Tuesday, October 13, 2026

SED Energy: The 40% Dividend. Signal or Noise?

SED Energy's proposed Ventura merger projects a 22% to 40% dividend yield, but idle tender barges, debt and repayments materially reduce distributable cash flow.

SBDXF $497M

Cannibal Stocks 45h ago 6 clicks

47h ago PKE $592M

Monte Investments Market Brief Vol. CXXXI

Monte Independent Investment Research 4 clicks

Oct 12 GONYF $499M

H&R REIT, an opportunity in a corrupt process

Nugget Capital Partner's Substack 2 clicks

From X

@calvinblissett Oct 12 4 clicks

Calvin Blissett on X

Too small, you could buy for triple the stock price and do beautifully as a private equity firm even given the worst case outcome due to cybersecurity which is loss of momentum in sales and a bit of churn. Would be more than made up for by the amount of leverage $CCLD could withstand, how many acquisitions they could do with a deeper and cheaper cost of capital

@stockgutter Oct 12

SG on X

$IONQ is down 48.66% over the past year. So its 2x inverse ETF must be up a lot, right? Nope. $IONZ is down a whopping 86%. The 2x bull ETF $IONX is even worse, down 91.79%. These instruments are toxic. https://t.co/oGxZrq6Xy1

@calvinblissett Oct 12

Calvin Blissett on X

Ever since I started following $CCLD I thought it was a great LBO candidate. This thing belongs in a PE portfolio and whoever LBOs will do very well, I would love to participate. $85m market cap, around $120m EV roughly. Can support a lot of leverage due to subscription/reoccurring cash flows. It is cheap in absolute (circa 3x FCF). It is at 1/4 the average multiple arguably worse peers have transacted at (maybe even less by now). Long runway for continued acquisition playbook (management said constantly evaluating 2k opportunities). Acquisition playbook targets distressed RCM companies, cuts costs due to CCLD offshore cheap labor and cross and upsells to existing sticky customers, $CCLD offers a broad suite of products and are implementing adn devloping AI products. Acquisitions earn 20-40% in 6 months. Prices paid are .5-1x Revenues way towards the lower end. Risk: 2026 guidance requires aggresive H2 and cybersecurity incident If anyone is interested in a LBO or pushing for a sale, please reach out, I have done and will do extensive diligence.

@calvinblissett Oct 12

Calvin Blissett on X

This one has been lurking on Joel Greenblatts magic formula for a while; I read this and am intrigued. Est 5x earnings with identifiable catalysts, pretty easy double using conservative multiples that don't credit growth. $TZOO https://t.co/mul6u2izKS

@calvinblissett Oct 12

Calvin Blissett on X

I listened to all Whitney Wolfe Heard interviews, that gave me a lot of confidence she would/will improve the consumer experience relentlessly, the business wasn’t/isn’t declining as much as perceived or sentiment makes it out to be. Even if it continued melting at the current pace and never growing the FCF would create immense value for equity holders. I don’t think it will continue melting though as they update and iterate on the experience and resume marketing spend. I think resuming marketing spend would be a big catalyst in terms of returning to growth that wasn’t reflected in the stock . $BMBL

@DeepSailCapital Oct 12

Deep Sail Capital on X

@stretchmikep I put on an industry short of genetic data companies early last week, $TEM, $CDNA, $DNA, and $ABSI Other than that a couple of stocks with good short activist write ups like $EQPT

@Fierce__beast Oct 12

Fierce_beast on X

@stoic_point $EVLV what you think the company actually earns LTM and NTM on a per share basis? Assuming SBC is a real expense, and replacing and growing their units as real costs.

@calvinblissett Oct 12 1 click

Calvin Blissett on X

@taobanker Man try $CCLD

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Helus Pharma's HLP003 Phase 3 depression data is due in 4Q26, with $166.4 million in cash and dilution risk from a $100 million ATM…

HELP $767M

Petri Dish Reports Oct 11 3 clicks

Hippo Holdings ($HIPO): The Insurtech That Stopped Chasing Hype and Started Making Money

Hippo’s insurance platform posted 61% premium growth, a 95.8% combined ratio and a fifth profitable quarter as it shifted toward carrier…

HIPO $906M

Substack von Philipp Oct 10 8 clicks

Brazil Potash: Bull Case Is Starting To (Slowly) Bloom

Brazil Potash has secured court support and a power agreement, but financing, dilution and potash-price-sensitive EBITDA remain central…

GRO $130M

Wolf Report Oct 10 3 clicks

Hyster Yale (HY) Multibagger potential as confluence of negatives subside. Attractive after markets part services model

Hyster-Yale trades at 0.16 times sales as lift-truck bookings rebound and restructuring targets $85 million to $100 million in annual…

HY $573M

Calvin Blissett Oct 9 3 clicks

Namib Minerals: Research Note

Namib Minerals posted H1 adjusted EBITDA of $19.0 million, up 76%, as higher gold prices offset lower production.

NAMM $55M

Atrium Research - Equity Research Oct 8 1 click

Lesaka: A $4.69 Stock With a $20–30 Case

Lesaka CEO Ali Mazanderani has bought more than $10 million of stock while pursuing a $20 to $30 valuation case through targeted…

LSAK $405M

Mispriced Assets Oct 8 5 clicks

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

CCOI $430M

Stock Thoughts Oct 7 3 clicks

Lesaka: Why He's Betting Big | Ali Mazanderani | Ep. 5

Lesaka’s executive chairman has invested more than $10 million personally and targets EPS compounding above 40% through consumer, merchant…

LSAK $405M

Mispriced Assets Oct 7 2 clicks

VersaBank: Expensive, But Growth Still Justifies A Buy

VersaBank's Q3 revenue rose 23% and adjusted net income 27%, while a 2.19% net interest margin and 19.15x forward earnings temper its 2027…

VBNK $707M

Grassroots Trading Oct 6 1 click

MGP Ingredients (MGPI) - The Hangover After the Whiskey Boom

MGP Ingredients trades at 0.74 times tangible book after whiskey oversupply drove sales declines and more than $400 million of impairments.

MGPI $308M

Dismissed & Asset-Backed Oct 6 1 click

BW · short

Babcock & Wilcox

Babcock & Wilcox is priced for AI power demand despite a one-time related-party project, with FY2028 EBITDA 35% below consensus implying…

BW $748M

Value Investors Club Jul 15 2 clicks

Solid Power Still Has Promise

Solid Power reported a $0.11 Q2 loss and $419.3 million of cash, with its electrolyte pilot line and BMW and SK On validation central to…

SLDP $518M

Quad 7 Capital Oct 5 2 clicks

DMRC: 31 retailers in line, up from one

Digimarc’s gift-card watermark pilot found zero fraud at Schnucks, while its retailer pipeline rose to 31 from one in 2025 despite…

DMRC $170M

Trade Ideas Flow Oct 5

Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.

Nyxoah's Genio implant could reach CCC patients after an FDA label expansion, targeting 30% of the obstructive sleep apnea device market by…

NYXH $130M

Stephen Tobin Oct 5 3 clicks

OMSE 2026-10-05

The Monday Morning Briefing: AI Drives Everything, Yet ROI on Massive Capex Remains Uncertain

Latticework’s briefing questions AI capex returns while featuring Close Brothers, Green Landscaping and OMS Energy Technologies.

OMSE $177M

Latticework by MOI Global Oct 5 2 clicks

40 Best Stock Pitches (28th-4th October) 🟢

Old Market Capital, a delisted holding company owning a rural fiber network, trades below comparable network valuations after institutional…

OMCC $27M

Capital Employed Oct 4 7 clicks

💥Leslies Term Lenders Toss a Life Preserver💥

Leslie’s and nine affiliates filed Chapter 11 in Texas on September 30, 2026, after 18 months of deteriorating performance.

LESL $1.6M

PETITION Oct 4 3 clicks

🤿New Chapter 11 Bankruptcy Filing - Leslie’s Inc.🤿

Leslie’s, the pool-supplies retailer, filed Chapter 11 after deteriorating operations, pricing and inventory missteps, and a burdensome…

LESL $1.6M

PETITION Oct 4 3 clicks

Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D

Pyxis Oncology's recent financing extends MICVO's runway to clinical milestones as the oncology candidate works to establish a safe,…

PYXS $168M

Myriam Alvarez Oct 4 2 clicks

EVI Industries. Margin inflection or fake out?

EVI Industries says its ERP and service-platform build is largely complete, testing whether 10.8% revenue growth can finally outpace…

EVI $238M

Kairos Research Oct 2 2 clicks

Tuesday, October 13, 2026

Calvin Blissett on X

SG on X

Calvin Blissett on X

Calvin Blissett on X

Calvin Blissett on X

Deep Sail Capital on X

Fierce_beast on X

Calvin Blissett on X

Investor Letters

Publications we follow

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 225

X accounts we follow

Investor letters we follow

Sectors